|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors were more frequently prescribed in East Anatolia (52.3%, p=0.001), and the prevalence of patients with heart failure and preserved ejection fraction using loop diuretics (48.8%, p=0.003) was higher in the Black Sea region.
|
30945522 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
|
30948834 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure.
|
31498767 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme gene DD polymorphism was associated with poorer survival and an increase in left ventricular mass in patients with idiopathic heart failure.
|
8752809 |
1996 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseline; these patients had 33% lower HF hospitalization rates (HR: 0.67; 95% CI: 0.54 to 0.82; p = 0.0002) and 47% lower mortality (HR: 0.63; 95% CI: 0.41 to 0.96, p = 0.0293) than controls.
|
28982501 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A novel human homologue of the angiotensin-converting enzyme (ACE), named ACE2, has been described but its role in human heart failure (HF) has not been elucidated.
|
16962475 |
2006 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A recent clinical trial PRARDIGM-HF demonstrated that this drug is superior to angiotensin-converting enzyme (ACE) inhibitors for improving the prognosis in the patients with heart failure, and this has resulted in the drug being included in clinical practice guidelines for the management of heart failure with reduced ejection fraction (EF).
|
29374807 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A total of 66 patients with heart failure and reduced ejection fraction already on guideline-recommended target dose ACE inhibitors or ARBs (equivalent to enalapril 10 mg twice daily) were switched to maximum-dose sacubitril-valsartan (200 mg twice daily).
|
31772613 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE2, the first known human homologue of angiotensin-converting enzyme (ACE), was identified from 5' sequencing of a human heart failure ventricle cDNA library.
|
10969042 |
2000 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure.
|
28679681 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation.
|
30067937 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Advanced Strategies in the Diagnosis and Treatment of Patients with Coronary Artery Disease and Heart Failure: When Heart Failure Causes Ischemia and Angiotensin Converting Enzyme Inhibitor and Betablockers Helps in Diuresis.
|
29283057 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
|
18586661 |
2008 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
All patients received β-blockers (BB) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACE-I/ARB), which were tapered off over a mean/median period of 3.3/2.5 years with only one case of worsening heart failure.
|
28462600 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
All study participants did not have prior heart failure or use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) up to 5 years prior.
|
31843974 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been recommended for patients with heart failure, their clinical and prognostic impact in the very acute phase of acute heart failure (AHF) is unclear, mainly because data on their safety and efficacy are lacking.
|
31218508 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although medical therapies including angiotensin converting enzyme inhibitors show inhibitory effects on post-infarct LV remodeling, the prognosis of patients with post-infarct heart failure is still poor.
|
28701679 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the first-in-class ARNi sacubitril/valsartan (LCZ696) reduced mortality and morbidity in heart failure (HF) with reduced ejection fraction (EF) compared to angiotensin converting enzyme inhibitor (ACEi), mechanistic data on ARNi are scarce.
|
29544929 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Amlodipine therapy was associated with 25% higher risk of heart failure (relative risk [RR]: 1.25, 95% confidence interval [CI], 1.05-1.49, P = .019) but 17% lower risk of stroke (RR: 0.83, [95% CI, 0.72-0.97], P = .009) without statistically significant effect on acute myocardial infarction (AMI) compared to major alternative antihypertensive therapy (MAAT), including β-blocker, diuretic, angiotensin-converting enzyme inhibitor, or angiotensin-receptor blocker.
|
29739234 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
An association between the DD allele of the angiotensin-converting enzyme gene and a poorer outcome in patients with heart failure has been found in whites.
|
10097225 |
1999 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
An increased plasma Ang-(1-7) level is linked to ACE inhibitor use, whereas acute HF reduced Ang-(1-7) levels and suppressed the Ang-(1-7)/Ang II ratio.
|
28209222 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anemic patients with HF tend to take angiotensin converting enzyme inhibitors (ACEI) less frequently.
|
28915848 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin receptor-neprilysin inhibitor (ARNI) combinations are the latest addition to the heart failure medical armamentarium, which is built on the cornerstone regimen of beta blockers, angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers, and aldosterone antagonists.
|
28185171 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats.
|
22123369 |
2011 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
As opposed to previously tested neprilysin inhibitors, sacubitril/valsartan represents a more effective method in reducing morbidity and mortality in heart failure, while preserving a safety profile comparable to well-established, standard, angiotensin-converting enzyme inhibitor's therapy.
|
28587583 |
2017 |